The prognosis of malignant gliomas remains poor, with median survival fewer than 20
months and a 5-year survival rate merely 5%. Their primary location in the central nervous …

Oncolytic viruses (OVs) are tumor-selective, multi-mechanistic antitumor agents. They kill
infected cancer and associated endothelial cells via direct oncolysis, and uninfected cells …

Cytotoxicity of tumor-specific T cells requires tumor cell-to-T cell contact-dependent
induction of classic tumor cell apoptosis and pyroptosis. However, this may not trigger …

Glioblastoma is the most aggressive form of malignant brain tumor. Standard treatment
protocols and traditional immunotherapy are poorly effective as they do not significantly …

Cancer immunotherapy and the emergence of immune checkpoint inhibitors have markedly
changed the treatment paradigm for many cancers. They function to disrupt cancer cell …

Neutrophils are innate immune cells that play an essential role during the clearance of
pathogens that can release chromatin structures coated by several cytoplasmatic and …

Twenty years of oncolytic virus development have created a field that is driven by the
potential promise of lasting impact on our cancer treatment repertoire. With the field …

Oncolytic virotherapy is a promising form of gene therapy for cancer, employing nature's own
agents to find and destroy malignant cells. The purpose of this review is to provide an …

Oncolytic viruses are one of the most promising novel therapeutics for malignant cancers.
They selectively infect and kill cancer cells while sparing the normal counterparts, expose …

Targeted therapy of cancer using oncolytic viruses has generated much interest over the
past few years in the light of the limited efficacy and side effects of standard cancer …